DPC 681 and DPC 684: Potent, Selective Inhibitors of Human Immunodeficiency Virus Protease Active against Clinically Relevant Mutant Variants

Human immunodeficiency virus (HIV) protease inhibitors (PIs) are important components of many highly active antiretroviral therapy regimens. However, development of phenotypic and/or genotypic resistance can occur, including cross-resistance to other PIs. Development of resistance takes place becaus...

תיאור מלא

מידע ביבליוגרפי

הוצא לאור ב:	Antimicrob Agents Chemother
Principais autores:	Kaltenbach, Robert F., Trainor, George, Getman, Daniel, Harris, Greg, Garber, Sena, Cordova, Beverly, Bacheler, Lee, Jeffrey, Susan, Logue, Kelly, Cawood, Pamela, Klabe, Ronald, Diamond, Sharon, Davies, Marc, Saye, Joanne, Jona, Janan, Erickson-Viitanen, Susan
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	American Society for Microbiology (ASM) 2001
נושאים:	Antiviral Agents
גישה מקוונת:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC90777/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11600351/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.45.11.3021-3028.2001
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!